BioNTech
在场
是其中之一......
BioNTech 是一家在股票代码 BNTX (DE) 下上市的公司。
BioNTech 在 3 个国家有直接业务。BioNTech 拥有 3家子公司，其中包括 BioNTech IMFS、BioNTech US 和 InstaDeep。
他们在：
涉及BioNTech的并购和融资。
- BioNTech 已收购 InstaDeep (公布2023八月1号).
- BioNTech has announced the acquisition of InstaDeep (公布2023一月12号).
高管
查看带有其 50 名主要高管的组织结构图
BioNTech 搜索最多的简介
高管在BioNTech变化
- Annemarie HanekampAnnemarie Hanekamp 将于20247月1作为 Chief Commercial Officer 加入公司 (新闻发布的2024三月21号).
- Sean Marett, Chief Business Officer and Chief Commercial Officer, 将于 20243月31 退休 (新闻发布的2024三月11号).
- James Ryan 曾任 Chief Legal Officer, 将于 20243月31 升职为 Chief Legal Officer and Chief Business Officer (新闻发布的2024三月11号).
创建提醒
跟踪 BioNTech 的高管变动
生物技术
BioNTech 拥有 2,276 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
BioNTech 的最新新闻稿
- Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design | BioNTech
- BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022 | BioNTech
- Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate | BioNTech
- Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY® | BioNTech
- Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age | BioNTech
- Statement on Patent Infringement Lawsuit in Germany | BioNTech
- Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine | BioNTech
- Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron | BioNTech
- BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer | BioNTech
- BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa | BioNTech
- View more press releases Close
通过电子邮件
